Fig. 4From: Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancersChallenges faced by liquid biopsy and PGx for their implementation in clinical practice for EGFR resistant and mutant lung cancer patients. Abbreviations: PGx: Pharmacogenomics; EGFR: Epidermal growth factor receptor; TKIs: Tyrosine kinase inhibitors; PTM: Post translational modifications; DDI: Drug-drug interaction; MRD: Minimal residual disease; TMB: Tumor mutational burdenBack to article page